Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Biomarkers for acute GVHD: can we predict the unpredictable?

Bone Marrow Transplantation volume 48, pages 755–760 (2013)Cite this article

Subjects

Abstract

Acute GVHD remains an important complication after allogeneic hematopoietic cell transplantation (HCT). Many efforts have been devoted to identifying potential noninvasive peripheral blood biomarkers to help improve the diagnosis or management of acute GVHD while avoiding invasive tissue biopsies. Early attempts to identify biomarkers focused on inflammatory cytokines, especially IL-2 or TNF-α, however, both of these and others were not specific for GVHD, often being elevated in the setting of generalized inflammation, accompanying other major complications of HCT as well. More recent efforts have focused on additional cytokines and other cell-surface molecules, which function in leukocyte trafficking and activation with the hope that these can also serve as targets for novel therapeutic approaches. Modern proteomic methods have allowed the screening of large numbers of patient samples and yielded several novel candidate biomarkers, including elafin and reg3α, which may not be directly involved in the immunological pathogenesis of GVHD, but may be unique biomarkers for end-organ injury. Combining these new molecules with traditionally identified cytokines to form an acute GVHD biomarker panel has recently shown the ability to predict outcomes in patients who develop acute GVHD. The ultimate goals of identifying a specific biomarker are to refine diagnosis, guide therapy and develop risk-adapted approaches in order to better treat patients and improve outcomes after allogeneic HCT. These approaches include differential treatment for patients who develop acute GVHD with a high-risk biomarker profile as well as pre-emptive therapy in patients after HCT prior to the development of symptoms. With the recent progress summarized below, these goals may soon be realized.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185–190.

    CAS  PubMed  Google Scholar 

  2. Grimm J, Zeller W, Zander AR . Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998; 21: 29–32.

    Article  CAS  Google Scholar 

  3. Foley R, Couban S, Walker I, Greene K, Chen CS, Messner H et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 769–773.

    Article  CAS  Google Scholar 

  4. Mathias C, Mick R, Grupp S, Duffy K, Harris F, Laport G et al. Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. J Hematother Stem Cell Res 2000; 9: 393–400.

    Article  CAS  Google Scholar 

  5. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559–1564.

    Article  CAS  Google Scholar 

  6. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224–1226.

    Article  CAS  Google Scholar 

  7. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–1016.

    CAS  PubMed  Google Scholar 

  8. Or R, Kalinkovich A, Nagler A, Weisman Z, Naparstek E, Weiss L et al. Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications. Cytokines Mol Ther 1996; 2: 243–250.

    CAS  PubMed  Google Scholar 

  9. Choi SW, Kitko CL, Braun T, Weisman Z, Naparstek E, Weiss L et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112: 1539–1542.

    Article  CAS  Google Scholar 

  10. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470–2475.

    Article  CAS  Google Scholar 

  11. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17: 1150–1156.

    Article  CAS  Google Scholar 

  12. Visentainer JE, Lieber SR, Persoli LB, Vigorito AC, Aranha FJ, de Brito Eid KA et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003; 31: 1044–1050.

    Article  CAS  Google Scholar 

  13. Liem LM, van Houwelingen HC, Goulmy E . Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 66: 863–871.

    Article  CAS  Google Scholar 

  14. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994; 13: 745–751.

    CAS  PubMed  Google Scholar 

  15. Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 510–517.

    Article  CAS  Google Scholar 

  16. Nakamura H, Komatsu K, Ayaki M, Kawamoto S, Murakami M, Uoshima N et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 2000; 106: S45–S50.

    Article  CAS  Google Scholar 

  17. Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000; 109: 652–657.

    Article  CAS  Google Scholar 

  18. Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A . Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol 2006; 15: 223–227.

    Article  CAS  Google Scholar 

  19. Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010; 45: 1546–1552.

    Article  CAS  Google Scholar 

  20. Uguccioni M, Meliconi R, Nesci S, Lucarelli G, Ceska M, Gasbarrini G et al. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood 1993; 81: 2252–2256.

    CAS  PubMed  Google Scholar 

  21. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E . Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant 2001; 28: 197–200.

    Article  CAS  Google Scholar 

  22. Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007; 110: 4535–4542.

    Article  CAS  Google Scholar 

  23. Seidel C, Ringden O, Remberger M . Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation 2003; 76: 423–426.

    Article  Google Scholar 

  24. Kircher B, Schumacher P, Nachbaur D . Granzymes A and B serum levels in allo-SCT. Bone Marrow Transplant 2009; 43: 787–791.

    Article  CAS  Google Scholar 

  25. Chen YB, McDonough S, Hasserjian R, Chen H, Coughlin E, Illiano C et al. Expression of CD30 in patients with acute graft-vs.-host disease. Blood 2012; 120: 691–696.

    Article  CAS  Google Scholar 

  26. Hubel K, Cremer B, Heuser E, von Strandmann EP, Hallek M, Hansen HP . A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2010; 23: 215–219.

    Article  Google Scholar 

  27. Butcher EC, Picker LJ . Lymphocyte homing and homeostasis. Science 1996; 272: 60–66.

    Article  CAS  Google Scholar 

  28. Springer TA . Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301–314.

    Article  CAS  Google Scholar 

  29. Sackstein R . A revision of Billingham’s tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 2–8.

    Article  Google Scholar 

  30. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS . Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191–4199.

    Article  CAS  Google Scholar 

  31. von Andrian UH, Mackay CR . T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020–1034.

    Article  CAS  Google Scholar 

  32. Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S et al. Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1066–1076.

    Article  Google Scholar 

  33. Chen YB, McDonough S, Chen H, Kennedy J, Ballen KK, Dey BR et al. Expression of α4β7 Integrin on Memory CD8+ T-cells is Increased in Patients at Presentation of Acute Intestinal Graft-vs-Host Disease. Biol Blood Marrow Transplant 2012; 18: S221.

    Article  Google Scholar 

  34. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007; 110: 3827–3832.

    Article  CAS  Google Scholar 

  35. Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 2008; 111: 4403–4412.

    Article  CAS  Google Scholar 

  36. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.

    Article  CAS  Google Scholar 

  37. Tilg H, Vedolizumab Kaser A. . A humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn’s disease. Curr Opin Investig Drugs 2010; 11: 1295–1304.

    CAS  PubMed  Google Scholar 

  38. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273–278.

    Article  CAS  Google Scholar 

  39. Paczesny S, Braun T, Vander Lugt A, Harris B, Fiema J, Hernandez J et al. A three biomarker panel at days 7 and 14 can predict development of grade II-IV acute graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: S167.

    Article  Google Scholar 

  40. Paczesny S, Levine JE, Braun TM, Ferrara JL . Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant 2009; 15: 33–38.

    Article  Google Scholar 

  41. Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 340–349.

    Article  CAS  Google Scholar 

  42. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 5511–5519.

    Article  CAS  Google Scholar 

  43. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010; 2: 13ra2.

    Article  Google Scholar 

  44. Harris AC, Ferrara JL, Levine JE, Braun T, Hogan J, Crawford J et al. Reg3α is a biomarker of graft versus host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2011; 17: S163–S164.

    Article  Google Scholar 

  45. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511–517.

    Article  CAS  Google Scholar 

  46. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854–3860.

    Article  CAS  Google Scholar 

  47. Rodriguez-Otero P, Porcher R, Peffault de Latour R, Contreras M, Bouhnik Y, Xhaard A et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastro-intestinal graft-versus-host disease. Blood 2012; 119: 5909–5917.

    Article  CAS  Google Scholar 

  48. Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant 1999; 24: 653–659.

    Article  CAS  Google Scholar 

  49. Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093–1096.

    Article  CAS  Google Scholar 

  50. Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003; 32: 205–211.

    Article  CAS  Google Scholar 

  51. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010; 45: 385–391.

    Article  CAS  Google Scholar 

  52. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005; 106: 4407–4411.

    Article  CAS  Google Scholar 

  53. Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34: 796–801.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, MA, USA

    Y-B Chen

  2. Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

    C S Cutler

Authors
  1. Y-B Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C S Cutler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y-B Chen.

Ethics declarations

Competing interests

Dr Y-B Chen has received funding for clinical trials from Millennium Pharmaceuticals, Inc. and has served as a consultant for and received funding for clinical trials from Seattle Genetics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, YB., Cutler, C. Biomarkers for acute GVHD: can we predict the unpredictable?. Bone Marrow Transplant 48, 755–760 (2013). https://doi.org/10.1038/bmt.2012.143

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.143

Keywords

This article is cited by

Search

Advanced search

Quick links